top of page

Novel Immunogenicity Risk Assessment Platform Facilitates Biologic Therapeutics Development

In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk – a critical characterization step in the candidate development process to ensure drug efficacy and safety in advance of clinical trials.

Today marks a significant advancement in this endeavor with the publication of „In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies“ in mAbs, which describes the ISPRI (Immunogenicity Screening and Protein Re-engineering Interface) toolkit, a web-based platform for in silico immunogenicity risk assessment of biologic therapeutics in preclinical development stages.

Aktuelle Beiträge

Alle ansehen

Comentarios


bottom of page